Canbridge Pharmaceuticals

Canbridge Pharmaceuticals é uma empresa listada sob o símbolo 1228 (CN).

Veja o organograma con seus 27 executivos principais

Biografias mais buscadas da Canbridge Pharmaceuticals

• James Xue, Chairman of the Board and Chief Executive Officer
• Lan Hu, Independent Director
• Peng Kuan Chan, Independent Non-Executive Director

Recentes movimentos de executivos em Canbridge Pharmaceuticals

• Derek Di Rocco, Non-Executive Director, deixou a Companhia  (Notícia publicada em 24 de novembro de 2023).

Criar um alerta
para seguir os movimentos de executivos da Canbridge Pharmaceuticals.

Canbridge Pharmaceuticals possui 1.860 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).

Popular M&A news in Farmacêutica

• MedMen has filed for bankruptcy protection  (publicado em 28 de abril de 2024).
• AstraZeneca has announced the acquisition of Fusion Pharma  (publicado em 23 de março de 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (publicado em 19 de março de 2024).

Outros contatos sugeridos na indústria do Farmacêutica

• Jean-Frédéric Paulsen - Executive Chairman of the Board da Ferring Pharmaceuticals
• Thierry Abribat - Chief Executive Officer da Amolyt Pharma
• Lucia Aleotti - Director da Menarini Group

Saiba mais sobre a indústria do Farmacêutica >

Últimos comunicados de imprensa de Canbridge Pharmaceuticals

• CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2023
• CANbridge and PUMCH announced the establishment of PUMCH- CANbridge Genetic Defect Rare Disease Innovation and Translation Base
• Foundation consolidated over time and for a rosy future | 2023 China Conference on Rare Diseases closed successfully
• CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at
  ESGCT 30^th Annual Congress
• CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China’s National Medical Products Administration
• CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China
• | CANbridge
• | CANbridge
• | CANbridge
• | CANbridge
• View more press releases Close

Redes sociais sobre Canbridge Pharmaceuticals

• Canbridge Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Canbridge Pharmaceuticals na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo James Xue

Ligue para a Canbridge Pharmaceuticals em +86 108...

Veja o organograma

Register to receive your alert

Relatório um erro